Danish procurers hail 87% Humira discount
Amgros, Denmark’s centralised procurement body for public hospitals, expects to realise a saving of almost 87% over the current price of Humira (adalimumab) following the advent of multisource biosimilar competition through a tender. The country’s medical council has just given the green light to substitute the autoimmune diseases treatment.
You may also be interested in...
Biosimilar adalimumab rivals to AbbVie’s Humira blockbuster continue to take market share in Germany, the latest market data demonstrates.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.